Chardan医疗保健收购 PHGE 深 沪
已收盘 01-09 16:00:00 美东时间
2.28
+0.040
+1.79%
华盛通- 最 高2.28
- 今 开2.18
- 成交量 6.09万股
- 最 低 2.07
- 昨 收 2.24
- 总市值 348.06万
- 52周最高 22.0571
- 市盈率 静 --
- 换手率 3.99%
- 52周最低 1.5004
- 委 比 0.00%
- 总股本 152.66万
- 历史最高 2261.00
- 量 比 1.75
- 振 幅 9.38%
- 历史最低 1.87
- 每 手 1
- 风险率 3.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BiomX Announces New Preferred Stock Financing and Warrants
BiomX ( ($PHGE) ) just unveiled an announcement. On December 26, 2025, BiomX In...
2025-12-30 06:47
BiomX Commences ~$3M Private Placement Of Series Y Convertible Preferred Stock
BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered
2025-12-29 21:05
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
BiomX Announces $3.0 Million Private Placement
BiomX Inc. has completed a $3.0 million private placement, issuing Series Y Convertible Preferred Stock with warrants, yielding 15% annual dividends. Proceeds support the evaluation of its phage therapy programs, including BX011 for Staphylococcus aureus infections, and strategic alternatives.
2025-12-29 13:00
PHGE shares are trading lower after the company discontinued its Phase 2b trial of BX004 in cystic fibrosis patients with chronic Pseudomonas aeruginosa infections.
PHGE shares are trading lower after the company discontinued its Phase 2b trial...
2025-12-08 20:41
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
BiomX Inc. has halted its Phase 2b clinical trial of BX004, a nebulized phage therapy for cystic fibrosis patients with chronic *Pseudomonas aeruginosa* infections, following high adverse event rates and recommendations from the Data Monitoring Committee. The company is implementing cost-cutting measures, including workforce reduction, while evaluating strategic alternatives. BiomX remains committed to advancing BX011, its fixed phage cocktail ta...
2025-12-08 12:30
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Praxis Precision Medicine (NASDAQ:PRAX) shares moved upwards by 33.6% ...
2025-12-06 01:05
BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review
BiomX works to address FDA device questions as a safety panel supports the BX004 trial, with topline results now expected in Q2 2026.
2025-11-27 02:23
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Shares of Autodesk Inc (NASDAQ:ADSK) rose sharply in pre-market trading after t...
2025-11-26 17:33
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
2025-11-26 10:07
